Strategic tools of influencing third world attitudes: The case of Soviet-U.S. rivalry
In: Comparative strategy, Band 11, Heft 4, S. 409-430
ISSN: 0149-5933
11 Ergebnisse
Sortierung:
In: Comparative strategy, Band 11, Heft 4, S. 409-430
ISSN: 0149-5933
World Affairs Online
In: https://ora.ox.ac.uk/objects/uuid:43b94c47-712f-4c0a-bfdf-878adbd032f0
Millennium development goal (MDG) of poverty reduction aims for halving of the head-count ratio over the period 1990-2015. Available studies draw attention to the gap between observed and required growth rates, the difficulties of sustaining the latter over time, and whether the policy stance of a government makes a difference to its overall performance. Trade-offs between growth and redistribution in achieving the MDG have also been examined. The present study builds on earlier work in several respects. A two-stage procedure is developed in which income per capita depends on agricultural GDP, a measure of openness of the economy, and regional characteristics in the first stage, and poverty depends on the (estimated) income per capita, a measure of income inequality, and regional characteristics in the second stage. Alternative estimation techniques - including a panel data method- have been employed to check the robustness of the results. The feasibility of halving poverty is examined at the global, regional and country levels. The gaps between required and observed growth rates of aggregate and agricultural income, and the trade-offs between growth and redistribution of income are assessed. While doubts persist about the feasibility of halving poverty in some regions, the results bring into sharper relief the potential of redistribution in achieving this goal.
BASE
In: https://ora.ox.ac.uk/objects/uuid:d4bb60d3-9234-49fd-8ff8-3a2a9090a61e
Millennium development goal (MDG) of poverty reduction aims for halving of the head-count ratio over the period 1990-2015. Available studies draw attention to the gap between observed and required growth rates, the difficulties of sustaining the latter over time, and whether the policy stance of a government makes a difference to its overall performance. Trade-offs between growth and redistribution in achieving the MDG have also been examined. The present study builds on earlier work in several respects. A two-stage procedure is developed in which income per capita depends on agricultural GDP, a measure of openness of the economy, and regional characteristics in the first stage, and poverty depends on the (estimated) income per capita, a measure of income inequality, and regional characteristics in the second stage. Alternative estimation techniques – including a panel data method- have been employed to check the robustness of the results. The feasibility of halving poverty is examined at the global, regional and country levels. The gaps between required and observed growth rates of aggregate and agricultural income, and the trade-offs between growth and redistribution of income are assessed. While doubts persist about the feasibility of halving poverty in some regions, the results bring into sharper relief the potential of redistribution in achieving this goal.
BASE
In: International social science journal: ISSJ, Band 45, Heft 1, S. 23
ISSN: 0020-8701
In: Peace research abstracts journal, Band 44, Heft 4, S. 456
ISSN: 0031-3599
In: Natural hazards and earth system sciences: NHESS, Band 14, Heft 12, S. 3231-3241
ISSN: 1684-9981
Abstract. Fragility functions in terms of flow depth, flow velocity and hydrodynamic force are developed to evaluate structural vulnerability in the areas affected by the 2009 Samoa earthquake and tsunami. First, numerical simulations of tsunami propagation and inundation are conducted to reproduce the features of tsunami inundation. To validate the results, flow depths measured in field surveys and waveforms measured by Deep-ocean Assessment and Reporting of Tsunamis (DART) gauges are utilized. Next, building damage is investigated by visually interpreting changes between pre- and post-tsunami high-resolution satellite images. Finally, the data related to tsunami features and building damage are integrated using Geographic Information System (GIS), and tsunami fragility functions are developed based on the statistical analyses. From the developed fragility functions, we quantitatively understood the vulnerability of a coastal region in American Samoa characterized by steep terrains and ria coasts.
In: Minimally invasive neurosurgery, Band 48, Heft 3, S. 132-135
ISSN: 1439-2291
Scientific discoveries that provide strong evidence of antitumor effects in preclinical models often encounter significant delays before being tested in patients with cancer. While some of these delays have a scientific basis, others do not. We need to do better. Innovative strategies need to move into early stage clinical trials as quickly as it is safe, and if successful, these therapies should efficiently obtain regulatory approval and widespread clinical application. In late 2009 and 2010 the Society for Immunotherapy of Cancer (SITC), convened an "Immunotherapy Summit" with representatives from immunotherapy organizations representing Europe, Japan, China and North America to discuss collaborations to improve development and delivery of cancer immunotherapy. One of the concepts raised by SITC and defined as critical by all parties was the need to identify hurdles that impede effective translation of cancer immunotherapy. With consensus on these hurdles, international working groups could be developed to make recommendations vetted by the participating organizations. These recommendations could then be considered by regulatory bodies, governmental and private funding agencies, pharmaceutical companies and academic institutions to facilitate changes necessary to accelerate clinical translation of novel immune-based cancer therapies. The critical hurdles identified by representatives of the collaborating organizations, now organized as the World Immunotherapy Council, are presented and discussed in this report. Some of the identified hurdles impede all investigators; others hinder investigators only in certain regions or institutions or are more relevant to specific types of immunotherapy or first-in-humans studies. Each of these hurdles can significantly delay clinical translation of promising advances in immunotherapy yet if overcome, have the potential to improve outcomes of patients with cancer.
BASE
In: Fox , BA , Schendel , D J , Butterfield , L H , Aamdal , S , Allison , J P , Ascierto , P A , Atkins , M B , Bartunkova , J , Bergmann , L , Berinstein , N , Bonorino , C C , Borden , E , Bramson , J L , Britten , C M , Cao , X , Carson , W E , Chang , A E , Characiejus , D , Choudhury , A R , Coukos , G , de Gruijl , T D , Dillman , R O , Dolstra , H , Dranoff , G , Durrant , L G , Finke , J H , Galon , J , Gollob , J A , Gouttefangeas , C , Grizzi , F , Guida , M , Hakansson , L , Hege , K , Herberman , R B , Hodi , F S , Hoos , A , Huber , C , Hwu , P , Imai , K , Jaffee , E M , Janetzki , S , June , C H , Kalinski , P , Kaufmann , H L , Kawakami , K , Kawakami , Y , Keilholtz , U , Khleif , S N , Kiessling , R , Kotlan , B , Kroemer , G , Lapointe , R , Levitsky , H I , Lotze , M T , Di Maio , M , Marschner , J P , Mastrangelo , M J , Masucci , G , Melero , I , Nelief , C , Murphy , W J , Nelson , B , Nicolini , A , Nishimura , M I , Odunsi , K , Ohashi , P S , O'Donnell-Tormey , J , Old , L J , Ottensmeier , C , Papamichail , M , Parmiani , G , Pawelec , G , Proietti , E , Qin , S , Rees , R , Ribas , A , Ridolfi , R , Ritter , G , Rivoltini , L , Romero , P J , Salem , M L , Scheper , R J , Seliger , B , Sharma , P , Shiku , H , Singh-Jasuja , H , Song , W , Straten , P T , Tahara , H , Tian , Z , van der Burg , S H , von Hoegen , P , Wang , E , Welters , M J , Winter , H , Withington , T , Wolchok , J D , Xiao , W , Zitvogel , L , Zwierzina , H , Marincola , F M , Gajewski , T F , Wigginton , J M & Disis , M L A 2011 , ' Defining the Critical Hurdles in Cancer Immunotherapy ' , Journal of Translational Medicine , vol. 9 , no. 1 , 214 . https://doi.org/10.1186/1479-5876-9-214
Scientific discoveries that provide strong evidence of antitumor effects in preclinical models often encounter significant delays before being tested in patients with cancer. While some of these delays have a scientific basis, others do not. We need to do better. Innovative strategies need to move into early stage clinical trials as quickly as it is safe, and if successful, these therapies should efficiently obtain regulatory approval and widespread clinical application. In late 2009 and 2010 the Society for Immunotherapy of Cancer (SITC), convened an "Immunotherapy Summit" with representatives from immunotherapy organizations representing Europe, Japan, China and North America to discuss collaborations to improve development and delivery of cancer immunotherapy. One of the concepts raised by SITC and defined as critical by all parties was the need to identify hurdles that impede effective translation of cancer immunotherapy. With consensus on these hurdles, international working groups could be developed to make recommendations vetted by the participating organizations. These recommendations could then be considered by regulatory bodies, governmental and private funding agencies, pharmaceutical companies and academic institutions to facilitate changes necessary to accelerate clinical translation of novel immune-based cancer therapies. The critical hurdles identified by representatives of the collaborating organizations, now organized as the World Immunotherapy Council, are presented and discussed in this report. Some of the identified hurdles impede all investigators; others hinder investigators only in certain regions or institutions or are more relevant to specific types of immunotherapy or first-in-humans studies. Each of these hurdles can significantly delay clinical translation of promising advances in immunotherapy yet if overcome, have the potential to improve outcomes of patients with cancer. © 2011 Fox et al; licensee BioMed Central Ltd.
BASE
Background Several studies have shown that diabetes confers a higher relative risk of vascular mortality among women than among men, but whether this increased relative risk in women exists across age groups and within defined levels of other risk factors is uncertain. We aimed to determine whether differences in established risk factors, such as blood pressure, BMI, smoking, and cholesterol, explain the higher relative risks of vascular mortality among women than among men. Methods In our meta-analysis, we obtained individual participant-level data from studies included in the Prospective Studies Collaboration and the Asia Pacific Cohort Studies Collaboration that had obtained baseline information on age, sex, diabetes, total cholesterol, blood pressure, tobacco use, height, and weight. Data on causes of death were obtained from medical death certificates. We used Cox regression models to assess the relevance of diabetes (any type) to occlusive vascular mortality (ischaemic heart disease, ischaemic stroke, or other atherosclerotic deaths) by age, sex, and other major vascular risk factors, and to assess whether the associations of blood pressure, total cholesterol, and body-mass index (BMI) to occlusive vascular mortality are modified by diabetes. Results Individual participant-level data were analysed from 980 793 adults. During 9·8 million person-years of follow-up, among participants aged between 35 and 89 years, 19 686 (25·6%) of 76 965 deaths were attributed to occlusive vascular disease. After controlling for major vascular risk factors, diabetes roughly doubled occlusive vascular mortality risk among men (death rate ratio [RR] 2·10, 95% CI 1·97–2·24) and tripled risk among women (3·00, 2·71–3·33; χ2 test for heterogeneity p<0·0001). For both sexes combined, the occlusive vascular death RRs were higher in younger individuals (aged 35–59 years: 2·60, 2·30–2·94) than in older individuals (aged 70–89 years: 2·01, 1·85–2·19; p=0·0001 for trend across age groups), and, across age groups, the death RRs were higher among women than among men. Therefore, women aged 35–59 years had the highest death RR across all age and sex groups (5·55, 4·15–7·44). However, since underlying confounder-adjusted occlusive vascular mortality rates at any age were higher in men than in women, the adjusted absolute excess occlusive vascular mortality associated with diabetes was similar for men and women. At ages 35–59 years, the excess absolute risk was 0·05% (95% CI 0·03–0·07) per year in women compared with 0·08% (0·05–0·10) per year in men; the corresponding excess at ages 70–89 years was 1·08% (0·84–1·32) per year in women and 0·91% (0·77–1·05) per year in men. Total cholesterol, blood pressure, and BMI each showed continuous log-linear associations with occlusive vascular mortality that were similar among individuals with and without diabetes across both sexes. Interpretation Independent of other major vascular risk factors, diabetes substantially increased vascular risk in both men and women. Lifestyle changes to reduce smoking and obesity and use of cost-effective drugs that target major vascular risks (eg, statins and antihypertensive drugs) are important in both men and women with diabetes, but might not reduce the relative excess risk of occlusive vascular disease in women with diabetes, which remains unexplained. Funding UK Medical Research Council, British Heart Foundation, Cancer Research UK, European Union BIOMED programme, and National Institute on Aging (US National Institutes of Health).
BASE